ELN584090

**ELN584090** is an investigational compound developed by Elan Pharmaceuticals as part of a portfolio of related molecules (including ELN584092, ELN584105, ELN584164, and ELN584095) transferred to Neotope Biosciences (later Prothena Corporation) in 2012 via intellectual property agreements. It is classified under general immunotherapy approaches, potentially involving active or passive immunotherapeutic strategies targeting protein aggregates, though specific indications like synucleinopathies (e.g., Parkinson's disease) or amyloid-beta related neurodegenerative conditions are associated with the broader IP portfolio. No mechanism of action, clinical trial data, or development status specific to ELN584090 is documented in available records; it appears to be an early-stage research compound with limited public disclosure.[1][8]